Document is current
Any future updates will be listed below
-
Authors
Liu, Fang-Yuan
Cho, Young-Lai
Fridayana, Fitri Rahma
Niloofar, Lashkari
Vo, Minh Nhat
Huang, Yan
Limanjaya, Anita
Kwon, Mi-Hye
Ock, Jiyeon
Lee, Seon-Jin https://orcid.org/0000-0001-7214-7536
Yin, Guo Nan https://orcid.org/0000-0002-2512-7337
Lee, Nam-Kyung
Ryu, Ji-Kan
-
Funding
Funding for this research was provided by:
Ministry of Science, ICT and Future Planning (NRF-2021R1A5A2031612)
National Research Foundation of Korea (2022R1A2B5B02001671)
Ministry of Health and Welfare (RS-2023-00217918)
- License Information
-
More Information
Article History
Received: 18 March 2024
Revised: 5 September 2024
Accepted: 30 September 2024
First Online: 1 January 2025
Competing interests
: N-KL is an inventor of the Tie2-agonistic antibody MT-100, and he is a founder and stockholder of MabTics Co., Ltd., which has the right to use MT-100. The remaining authors declare no potential conflicts of interest.
